These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 36108558)

  • 1. Recurrent or primary metastatic cervical cancer: current and future treatments.
    Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
    ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
    Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
    Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
    Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
    Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
    Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
    Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
    Luu K; Chu A; Chang B
    J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in paclitaxel combinations for treating cervical cancer.
    Della Corte L; Barra F; Foreste V; Giampaolino P; Evangelisti G; Ferrero S; Bifulco G
    Expert Opin Pharmacother; 2020 Apr; 21(6):663-677. PubMed ID: 32037907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
    Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
    Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immunotherapy in cervical cancer.
    Grau JF; Farinas-Madrid L; Garcia-Duran C; Garcia-Illescas D; Oaknin A
    Int J Gynecol Cancer; 2023 Mar; 33(3):403-413. PubMed ID: 36878562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
    Turinetto M; Valsecchi AA; Tuninetti V; Scotto G; Borella F; Valabrega G
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I).
    Yang ST; Wang PH; Liu HH; Chang CW; Chang WH; Lee WL
    Taiwan J Obstet Gynecol; 2024 Sep; 63(5):637-650. PubMed ID: 39266144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
    Mutlu L; Tymon-Rosario J; Harold J; Menderes G
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational therapies for the treatment of advanced cervical cancer.
    Duenas-Gonzalez A
    Expert Opin Pharmacother; 2023 Jan; 24(1):73-81. PubMed ID: 35653267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
    Ilhan Y; Tatli AM; Teker F; Onder AH; Kose F; Geredeli C; Karaagac M; Kaplan MA; Inanc M; Goktas Aydin S; Kargi A; Arak H; Ozturk B; Besen AA; Selvi O; Korkmaz M; Oruc Z; Bozkurt O; Bilici A; Bayram S; Dae SA; Ozdogan M; Coskun HS; Sezgin Goksu S
    Int J Gynecol Cancer; 2022 Apr; 32(4):502-507. PubMed ID: 35086927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tisotumab vedotin in recurrent or metastatic cervical cancer.
    Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
    Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.